Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults. Mol Ther Methods Clin Dev, 3, 16061. presented at the 2016. doi:10.1038/mtm.2016.61. (2016).
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 26(22), 2788-95. presented at the 2008 May 23. doi:10.1016/j.vaccine.2008.02.071. (2008).
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine, 25(11), 2120-7. presented at the 2007 Mar 01. doi:10.1016/j.vaccine.2006.11.016. (2007).
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled. J Virol, 80(10), 4717-28. presented at the 2006 May. doi:10.1128/JVI.80.10.4717-4728.2006. (2006).
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine, 24(4), 417-25. presented at the 2006 Jan 23. doi:10.1016/j.vaccine.2005.08.041. (2006).